|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0001675,
umls-concept:C0002423,
umls-concept:C0013072,
umls-concept:C0078569,
umls-concept:C0178602,
umls-concept:C0439423,
umls-concept:C0443220,
umls-concept:C0547043,
umls-concept:C1269683,
umls-concept:C1533126,
umls-concept:C2603343
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
2009-12-16
|
|
pubmed:abstractText |
Serotonin (HT) and noradrenaline (NA) reuptake inhibitors (SNRIs) are commonly used as first line treatment of major depressive disorders (MDD). As compared to tricyclic antidepressants, they have proved similar efficacy and better tolerability. Milnacipran (MLN) (Ixel) and venlafaxine (VLF) (Effexor) are two SNRIs pharmacologically differing by their NA/HT ratio of potency: 1:1 and 1:30, respectively.
|
|
pubmed:language |
fre
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
0013-7006
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
35
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
595-604
|
|
pubmed:meshHeading |
pubmed-meshheading:20004291-Adult,
pubmed-meshheading:20004291-Aged,
pubmed-meshheading:20004291-Ambulatory Care,
pubmed-meshheading:20004291-Antidepressive Agents,
pubmed-meshheading:20004291-Cyclohexanols,
pubmed-meshheading:20004291-Cyclopropanes,
pubmed-meshheading:20004291-Depressive Disorder, Major,
pubmed-meshheading:20004291-Dose-Response Relationship, Drug,
pubmed-meshheading:20004291-Double-Blind Method,
pubmed-meshheading:20004291-Drug Administration Schedule,
pubmed-meshheading:20004291-Female,
pubmed-meshheading:20004291-France,
pubmed-meshheading:20004291-Humans,
pubmed-meshheading:20004291-Male,
pubmed-meshheading:20004291-Middle Aged,
pubmed-meshheading:20004291-Personality Inventory,
pubmed-meshheading:20004291-Serotonin Uptake Inhibitors,
pubmed-meshheading:20004291-Suicide,
pubmed-meshheading:20004291-Young Adult
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
[Milnacipran and venlafaxine at flexible doses (up to 200 mg/d) in the outpatient treatment of adults with moderate-to-severe major depressive disorder: a 24-week randomised, double blind exploratory study].
|
|
pubmed:affiliation |
Service de santé mentale et thérapeutique, centre hospitalier Sainte-Anne, 1, rue Cabanis, 75674 Paris cedex 14, France. jp.olie@ch-sainte-anne.fr
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
English Abstract,
Randomized Controlled Trial,
Multicenter Study
|
